Vancouver, Canada Feb 26, 2021.  — TMFOX VENTURE PARTNERS, a boutique investment banker and venture investor for global healthcare reached an agreement with saNOtize Research and Development Corp, a Vancouver-based bio-tech company for the endeavor of technology license and new market development partnership.

saNOtize utilizes the unique antimicrobial and immunomodulating properties of Nitric Oxide to treat diseases of the respiratory system and the skin. The company’s platform technology, NORS^TM, can treat a variety of topical infections. From sinusitis via nasal lavage and the flu via nasal spray, to acne via topical gel. Dr. Gilly Regev, PhD and Dr. Chris Miller, PhD, BA, RT are co-founders of SaNOtize.  Dr. Regev and Dr. Miller are among a small group of people who are experts at using nitric oxide therapeutically.

SaNOtize is also working diligently with Health Canada and the FDA to obtain approval for the emergency release of preventative treatment for healthcare workers and high-risk individuals exposed to SARS-CoV-2.

Commenting on the agreement, Andy Yu, President of TMFOX, said, “In considering the getting worse infection disease and strong demand for skincare, We believe the Asia market,especially China market, has the great potential to benefit back the long time hard-working on R&D. ”

About TMFOX VENTURE PARTNERS

TMFOX focuses on the evolution of global Healthcare and is committed to empowering its clients with cross-border funding, business development, and risk management. TMFOX offers holistic solutions that help clients grow competitive in this constantly evolving market. Founded in 2009 in Shenzhen in China by Andy Yu, the boutique investment bank has operations in 6 cities across China and 3 international cities such as Vancouver, Seattle, and Boston in North American.